Form D · Biotechnology
Cadrenal Therapeutics, Inc.
Ponte Vedra, FL · CIK 0001937993
Offering snapshot reported Jul 15, 2026 · SEC filing
- Reported sold
- $8.84M Offering amount: $8.84M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2026 | Initial | $8,843,849 | No comparison | 1 | SEC filing |
| Apr 6, 2026 | Initial | $7,923,235 | No comparison | 1 | SEC filing |
| Dec 31, 2025 | Initial | $4,396,329 | No comparison | 4 | SEC filing |
| Nov 14, 2024 | Initial | $9,428,594 | No comparison | 5 | SEC filing |
| Jul 18, 2023 | Initial | $7,500,001 | No comparison | 1 | SEC filing |
| Dec 8, 2022 | Initial | $250,000 | No comparison | 2 | SEC filing |
| Jul 25, 2022 | Initial | $150,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $315K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-590962
The total offering amount reflects the total gross proceeds to be received assuming cashexercise of all warrants issued in the private placement.
The placement agent received a 7.0% cash fee of $210,000, 1.0% management fee of $30,000, non-accountable expenses of $25,000, accountable expenses of $50,000 and warrants to purchase 62,4000 shares of common stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 |
Source: Form D, filed Jul 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey S. Cole | Executive |
| Jeff Cole | Executive |
| James J. Ferguson | Executive |
| Lee Golden | Director |
| Robert Lisicki | Director |
| Douglas W. Losordo | Executive |
| John R. Murphy | Director |
| Quang X. Pham | Director, Executive |
| John P. Sharp | Executive |
| Matthew Szot | Executive |
| Glynn Wilson | Director |
| Steven Zelenkofske | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
822 A1 A North, Suite 306
Ponte Vedra, FL, 32082
Phone: (904) 300-0701
Ponte Vedra, FL, 32082
Phone: (904) 300-0701